Skip to main content

Table 2 Wilcoxon rank sum tests with p-values adjusted for multiple comparisons for gene methylation levels and tumor characteristics

From: Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome

Tumor Characteristic Group

Gene

Median Methylation Levelof the Gene

 

Adaptive Hochberg p-value for the Wilcoxon ranked sum tests

ER

 

ER+

ER-

 
 

RIL

16.75%

21.90%

0.58

 

HIN-1

17.00%

7.90%

0.002

 

RASSF1A

23.10%

8.90%

<0.001

 

CDH13

8.60%

8.35%

0.58

PR

 

PR+

PR-

 
 

RIL

14.70%

24.65%

0.012

 

HIN-1

19.50%

8.60%

0.002

 

RASSF1A

23.10%

13.4%

0.019

 

CDH13

8.60%

8.70%

0.14

Tumor Size

 

≤ 2 cm

>2 cm

 
 

RIL

15.45%

21.30%

0.002

 

HIN-1

12.10%

16.30%

0.45

 

RASSF1A

13.60%

21.40%

0.09

 

CDH13

7.30%

9.65%

0.002

S-phase

 

≤ 10%

> 10%

 
 

RIL

14.80%

24.55%

0.036

 

HIN-1

16.10%

12.65%

0.39

 

RASSF1A

18.50%

15.30%

0.17

 

CDH13

7.05%

9.30%

0.31

Ploidy

 

Diploid

Aneuploid

 
 

RIL

14.80%

23.70%

< 0.001

 

HIN-1

12.45%

16.20%

0.30

 

RASSF1A

14.90%

17.90%

0.93

 

CDH13

7.10%

8.80%

0.07